Incidence and risk factors of reactive histiocytic hyperplasia with hemophagocytosis in medical intensive care patients

por Strauss, R, Neureiter, D, Wehler, M, Westenburger, B, Kirchner, Th, Hahn, EG
Publicado 2002

Lack of complex I is associated with oncocytic thyroid tumours

por Zimmermann, F A, Mayr, J A, Neureiter, D, Feichtinger, R, Alinger, B, Jones, N D, Eder, W, Sperl, W, Kofler, B
Publicado 2009

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab

por Magnes, T., Melchardt, T., Hufnagl, C., Weiss, L., Mittermair, C., Neureiter, D., Klieser, E., Rinnerthaler, G., Roesch, S., Gaggl, A., Greil, R., Egle, A.
Publicado 2019

C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients

por Troppan, K T, Schlick, K, Deutsch, A, Melchardt, T, Egle, A, Stojakovic, T, Beham-Schmid, C, Weiss, L, Neureiter, D, Wenzl, K, Greil, R, Neumeister, P, Pichler, M
Publicado 2014

Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence

por Magnes, T., Wagner, S., Thorner, A.R., Neureiter, D., Klieser, E., Rinnerthaler, G., Weiss, L., Huemer, F., Zaborsky, N., Steiner, M., Weis, S., Greil, R., Egle, A., Melchardt, T.
Publicado 2021

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

por Stintzing, S, Wirapati, P, Lenz, H -J, Neureiter, D, Fischer von Weikersthal, L, Decker, T, Kiani, A, Kaiser, F, Al-Batran, S, Heintges, T, Lerchenmüller, C, Kahl, C, Seipelt, G, Kullmann, F, Moehler, M, Scheithauer, W, Held, S, Modest, D P, Jung, A, Kirchner, T, Aderka, D, Tejpar, S, Heinemann, V
Publicado 2019